<DOC>
	<DOCNO>NCT00274872</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know combination chemotherapy regimen effective treat colorectal cancer . PURPOSE : This randomized phase II/III trial study two combination chemotherapy regimens compare well work treat patient metastatic colorectal cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Colorectal Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient inoperable metastatic colorectal cancer treat oxaliplatin , leucovorin calcium , fluorouracil v without maintenance leucovorin calcium fluorouracil . - Demonstrate time disease control ( TDC ) increase 15 % 9 month maintenance therapy avoid . Secondary - Compare overall survival response rate patient treat regimen . - Compare salvage surgery rate patient treat regimen . - Compare tolerability regimens patient . - Compare quality life patient treat regimen . - Compare duration chemotherapy-free interval patient treat regimen . - Compare pharmacoeconomy pharmacogenetics regimens patient . OUTLINE : This randomize , control , open-label , multicenter study . Patients stratify accord participate center , performance status ( 0-1 v 2 ) , number metastatic site ( 1 v &gt; 1 ) , age ( 18-50 year v 51-75 year v 76-80 year ) , adjuvant chemotherapy , baseline alkaline phosphatase ( ≤ 3 time upper limit normal [ ULN ] v &gt; 3 time ULN ) . Patients randomize 1 2 treatment arm . Arm I - FOLFOX chemotherapy : Patients receive oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously 46 hour day 1 2 . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Patients proceed maintenance chemotherapy . - Maintenance chemotherapy : Patients receive leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously 46 hour day 1 2 . Courses repeat every 14 day absence disease progression unacceptable toxicity . Patients disease progression maintenance chemotherapy receive 6 additional course FOLFOX . Patients continued disease progression receive additional course FOLFOX proceed irinotecan-based chemotherapy study . Arm II - FOLFOX chemotherapy : Patients receive 6 course FOLFOX arm I . Patients disease progression FOLFOX receive 6 additional course FOLFOX . Patients continued disease progression receive additional course FOLFOX proceed irinotecan-based chemotherapy study . In arm , patient stable respond disease may undergo surgical resection completion initial 6 course FOLFOX . Quality life assess baseline , course 4 6 , every 2-3 month thereafter . After completion study treatment , patient follow 1 month every 3 month thereafter . PROJECTED ACCRUAL : A total 600 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove adenocarcinoma colon rectum Metastatic disease No metastases involve bone Inoperable disease ( i.e. , suitable complete surgical resection ) Measurable evaluable disease Measurable disease define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional CT scan OR ≥ 10 mm spiral CT scan No symptomatic ascites pleural effusion evacuate No CNS metastasis PATIENT CHARACTERISTICS : WHO OR ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelets ≥ 100,000/mm^3 Creatinine &lt; 3 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 5 time ULN No peripheral neuropathy ≥ grade 1 No total partial bowel obstruction Not pregnant nursing Fertile patient must use effective contraception No uncontrolled hypercalcemia No concurrent prior malignancy , except adequately treat carcinoma situ uterine cervix basal squamous cell carcinoma skin cancer complete remission ≥ 5 year No uncontrolled congestive heart failure No angina pectoris No hypertension No arrhythmias No history significant neurologic psychiatric disorder No active infection No serious nonmalignant disease PRIOR CONCURRENT THERAPY : No prior chemotherapy and/or immunotherapy metastatic disease Prior adjuvant chemotherapy allow provide progressionfree interval completion adjuvant chemotherapy &gt; 6 month No concurrent anticancer treatment No participation another clinical trial investigational drug within 30 day prior randomization No concurrent investigational treatment No concurrent radiotherapy No concurrent cold cap prevention alopecia ice mouth rinse prevention stomatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>